| 14.47 -0.55 (-3.66%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.1  |
1-year : | 22.43 |
| Resists | First : | 17.21 |
Second : | 19.2 |
| Pivot price | 15.66 |
|||
| Supports | First : | 13.98 |
Second : | 11.63 |
| MAs | MA(5) : | 15.52 |
MA(20) : | 15.99 |
| MA(100) : | 17.63  |
MA(250) : | 14.46 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 31.7 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 27.4 | Low : | 8.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CBIO ] has closed above bottom band by 12.9%. Bollinger Bands are 46.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.34 - 15.41 | 15.41 - 15.49 |
| Low: | 13.78 - 13.87 | 13.87 - 13.96 |
| Close: | 14.3 - 14.45 | 14.45 - 14.59 |
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Fri, 31 Jul 2026
Crescent Biopharma: Q2 Earnings Snapshot - theheraldreview.com
Thu, 30 Jul 2026
Crescent Biopharma (NASDAQ: CBIO) registers 18.2M shares for investor resale - Stock Titan
Thu, 30 Jul 2026
Crescent Biopharma reports Q2 2026 net loss $24.8M, cash $171.6M and $143.7M public offering - TradingView
Thu, 30 Jul 2026
Crescent Biopharma: Q2 Earnings Snapshot - kens5.com
Thu, 30 Jul 2026
Crescent Biopharma (Nasdaq: CBIO) posts Q2 loss, extends cash runway to 2028 - Stock Titan
Thu, 30 Jul 2026
Crescent expects trial data in 2027 after $143.7M offering - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 1.851e+007 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 3,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 380 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1.188e+007 % |
| Gross Profit (p.s.) | 0.39 |
| Sales Per Share | 0.39 |
| EBITDA (p.s.) | -5.54 |
| Qtrly Earnings Growth | -5.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 36.8 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.74e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|